Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying Aβ1–43/IL-10 cDNA  by Hara, Hideo et al.
M
v
H
a
b
c
d
e
f
a
A
A
K
A
I
S
A
1
c
t
m
[
n
a
A
g
i
p
p
e
S
t
p
1
0
dVaccine 29 (2011) 7474– 7482
Contents lists available at ScienceDirect
Vaccine
j ourna l ho me  pag e: www.elsev ier .com/ locate /vacc ine
ucosal  immunotherapy  in  an  Alzheimer  mouse  model  by  recombinant  Sendai
irus  vector  carrying  A1–43/IL-10  cDNA
ideo  Haraa,1,  Akihiro  Mourib,c,1,  Yoshikazu  Yonemitsud,  Toshitaka  Nabeshimab,c, Takeshi  Tabirae,f,∗
Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine, 5-1-1 Nabeshima, Saga 849-8501, Japan
Department of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Meijo University, 150 Yagotoyama, Tenpaku, Nagoya, Aichi 468-8503, Japan
Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa, Nagoya, Aichi 466-8560, Japan
Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan
Department of Vascular Dementia Research, National Institute for Longevity Sciences, NCGG, 36-3 Gengo, Morioka, Obu, Aichi 474-8522, Japan
Department of Diagnosis, Prevention and Treatment of Dementia, Graduate School of Medicine, Juntendo University, 2-11-5-3F Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
 r  t  i  c  l  e  i  n  f  o
rticle history:
vailable online 29 July 2011
eywords:
lzheimer’s disease
a  b  s  t  r  a  c  t
Based  on  the  amyloid  cascade  hypothesis,  many  reports  have  indicated  that  immunotherapy  is  beneﬁcial
for  Alzheimer’s  disease  (AD).  We  developed  a mucosal  immunotherapy  for AD  by nasal  administration
of  recombinant  Sendai  virus  vector  carrying  A1–43  and  mouse  IL-10  cDNA.  Nasal  but not  intramus-
cular  administration  of  the  vaccine  induced  good  antibody  responses  to A. When  APP  transgenic  micemmunotherapy
endaivirus vector
myloid
(Tg2576)  received  this  vaccine  once  nasally,  the  A  plaque  burden  was  signiﬁcantly  decreased  8 weeks
after  without  inducing  inﬂammation  in  the  brain.  The  amount  of  A  measured  by  ELISA  was  also  reduced
in  both  soluble  and  insoluble  fractions  of  the  brain  homogenates,  and  notably  the  A  oligomer  (12-mer)
was  also  apparently  decreased.  Tg2576  mice  showed  signiﬁcant  improvement  in cognitive  functions
examined  at  3  months  after  vaccination.  Thus,  this  is an alternative  immunotherapy  for AD,  which  has
sive,  an advantage  in  non-inva
. Introduction
Alzheimer’s disease (AD) is characterized by progressive loss of
ognitive functions related to amyloid  (A)  deposits in the cen-
ral nervous system. Based on the amyloid cascade hypothesis [1],
any reports have indicated the efﬁcacy of immunotherapy for AD
2].  This strategy was originated by the ﬁnding that active immu-
ization with A peptide plus adjuvant showed effective clearance
nd prevention of amyloid deposits in PDAPP mice [3].
Although the phase IIa trial of AN1792, a mixture of synthetic
1–42 peptide and adjuvant QS21 was halted because of menin-
oencephalitis as the side effect [4],  pathological reports have
ndicated the effective removal of senile plaques in vaccinated
atients [5–7]. AN1792 also ameliorates cognitive functions of AD
atients [8–10], although another report showed no clinical ben-
ﬁt in spite of signiﬁcant clearance of senile plaque amyloid [11].
ince administration of some anti-A antibodies has also shown
he therapeutic efﬁcacy in animals [12,13], some clinical trials of
Abbreviations: AD, Alzheimer disease; A, amyloid -peptide; APP, amyloid
recursor protein; tg, transgenic.
 Data deposition: mouse IL-10 (accession no. NP 034678).
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Open access under CC BY-NC-ND license.safe  and  relatively  long  lasting  features.
© 2011 Elsevier Ltd. 
passive immunization are under investigation. However, repeated
injections of monoclonal anti-A antibody are required, which
may  produce anti-idiotype and neutralizing antibodies. Increases of
micro-hemorrhage and vasogenic edema have also been reported
after systemic administration of anti-A antibodies into APP-tg
mice and humans [14–16].  Furthermore, passive immunization is
not useful for prophylaxis for diseases with insidious onset such
as AD. Thus, active immunization, if it is safe and easy, still has an
advantage. One of the active immunizations is intramuscular injec-
tion of DNA encoding A [17,18]. However, repeated injections are
required, and it may require a strategy of suppressing T helper 1
(Th1) immune responses.
The mucosal immune system representing Peyer’s patch and
nasopharyngeal associated lymphoid tissue (NALT) has distinct
functions such as predominant humoral immune responses and
efﬁcient immune induction via mucosal tissue. To induce mucosal
immune responses nasal administration of A peptide and adju-
vant has been successful in mice [19,20].  However, use of
adjuvant induces T cell inﬁltration in the brain. Administration
of viral vectors carrying cDNA encoding genes of targeting anti-
gens can stimulate mucosal immune system without adjuvant
[21].
Open access under CC BY-NC-ND license.Now, we  have developed a new nasal vaccine for AD by using
the recombinant Sendai virus (SeV) vector. We  found an excellent
effect of the vaccine in APP-tg mice (Tg2576) pathologically and
functionally without inducing brain inﬂammation.
H. Hara et al. / Vaccine 29
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1:20. For quantiﬁcation of A in the insoluble fractions, we  used
-amyloid ELISA kit (Wako, Japan). The supernatant was  dilutedig. 1. A construct of SeV- A1–43/TSF-mIL-10 vector. Human A1–43 and mouse
L-10 cDNAs were inserted in SeV/TSF  vector.
. Materials and methods
.1. Ethics
This work was conducted in accordance with The Code of
thics of the World Medical Association (Declaration of Helsinki).
ll experiments were performed in accordance with Guidelines
or Animal Experiments of the NCGG/NILS animal experimenta-
ion committee and of Nagoya University School of Medicine. The
rocedures involving animals and their care conformed to the inter-
ational guidelines set out in “Principles of Laboratory Animal Care”
NIH publication no. 85-23, revised 1985).
.2. Mice
Tg2576 mice [22] expressing the Swedish mutation of APP
APPK670N, M671L) at high levels under control of the hamster
rion protein (PrP) promoter were obtained from Taconic Co. (USA).
nimals were kept in a speciﬁc-pathogen-free condition and fed ad
ibitum.
.3. Recombinant Sendai virus vector
We  developed recombinant SeV vector carrying human A1–43
DNA and mouse interleukin-10 (mIL-10) cDNA (rSeV-A). Recom-
inant SeV vector carrying LacZ cDNA (rSeV-LacZ) was used as
ontrol. The experiment was approved by the recombinant DNA
xperiment safety committee in the institutions.
In order to make the vaccine, we utilized F gene-deleted
on-transmissible SeV [23] further bearing temperature-sensitive
utations in M (G69E, T116A, and A183S), HN (A262T, G264R,
nd K461G) [24], P (L511F) and L (N1197S, K1795E) identiﬁed
n SeV strains capable of persistent infection in vitro [25]. Thus
enerated and named SeV/TSF  vector was used to construct the
eV18+A1–43/TSF-mIL10 vector carrying A1–43 gene with APP
ecretion signal [21] and mIL10 according to the method described
reviously with a little modiﬁcation [23,24,26] (Fig. 1). In brief,
1–43 gene was ampliﬁed with a pair of NotI-tagged primers
hat contained SeV-speciﬁc transcriptional regulatory signal
equences, 5′-ATTGCGGCCGCCAAGGTTCACTTATGCTGCCCGGTTT-
GCACTGCTCCTG-3′ and 5′-ATTGCGGCCGCGATGAACTTTCACCCT-
AGTTTTTCTTACTACGG TTAAGTCGCTATGACAACACCGCCCACCAT-
AGTCC-3′. The ampliﬁed fragment was introduced into the
otI site of the parental pSeV18+/TSF,  cDNA of SeV/TSF,  to
enerate pSeV18+A43/TSF.  mIL-10 (accession no. NP 034678)
DNA that was ampliﬁed with a pair of NotI-tagged primers, 5′-
CTTGCGGCCGCCAAAGTTCAATGCCTGGCTCAGCACTGCTATGCTG-
CTG-3′ and 5′-ATCCGCGGCCGCGATAACTTTCACCCTAAGTTTTTCT-
ACTACG GTTAGCTTTTCATTTTGATCATCATGTATGCTTC-3′, was
ubcloned into the F gene-deleted site of the LitmusSalINheIhfrag-
SF  carrying the SalI  and NheI digested fragment containing
 and HN genes from pSeV18+/TSF  in LITMUS38 (NEB) [27].
he SalI  and NheI digested fragment of pSeV18+A1–43/TSF
as substituted with the corresponding fragment of the
IL10 gene-introduced LitmusSalINheIhfrag-TSF. The cDNA
f SeV18+LacZ/TSF  (pSeV18+lacZ/TSF)  was  constructed in
imilar manner using an ampliﬁed fragment of LacZ [26]. (2011) 7474– 7482 7475
pSeV18+A1–43/TSF-mIL10 or pSeV18+LacZ/TSF  was  trans-
fected into 293T cells with T7-expressing plasmid. The T7-driven
recombinant SeV18+A1–43/TSF-mIL10 and SeV18+LacZ/TSF
RNA genomes were encapsulated by NP, P, and L proteins, which
were derived from their respective co-transfected plasmids. The
recovered SeV vectors were propagated using F protein-expressing
packaging cell line [23]. The virus titers were determined using
infectivity and were expressed in cell infectious units (CIU). The
SeV vectors were stored at −80 ◦C until use.
2.4. Vaccination with rSeV-Aˇ or rSeV-LacZ
rSeV was  diluted with PBS to give 5 × 106 CIU/head in a ﬁnal
volume of 0.02 ml,  and was  administered once nasally or intramus-
cularly (left quadriceps) to 12-month-old Tg2576 mice for analysis
of cognitive functions and body weight, or to 24-month-old Tg2576
mice for evaluation of amyloid burdens and A contents in the
brain. Control Tg2576 mice received rSeV-LacZ and were analyzed
in the same way.
2.5. Pathological study
Tg2576 mice received the vaccine nasally or intramuscularly at
the age of 24 months and were sacriﬁced 8 weeks after by CO2
asphyxiation. Their brains were removed and cut in half sagittally.
2.6. Serum antibodies against Aˇ42
Anti-human A antibody titers in the serum of nasally or
intramuscularly vaccinated mice with rSeV-A or rSeV-LacZ (n = 4
each) were quantiﬁed by a sandwich ELISA. Microtiter ELISA plates
were coated overnight at 4◦C with 2 g/ml of synthetic human
A1–42 in 0.1 M NaHCO3, pH 8.3, washed twice with washing
buffer, blocked with 1% BSA and 2% normal goat serum in PBS for
2 h at room temperature (RT), washed twice and incubated with
mouse serum samples diluted 1:500 in blocking buffer for 2 h at RT
while shaking, washed ×4 and incubated horseradish peroxidase-
conjugated goat-anti-mouse IgG for 2 h at RT, washed × 4 and
analyzed colorimetrically after incubation with the chromogen
substrate 3,3′,5,5′-tetramethylbenzidine (Kirkegaard & Perry Lab-
oratories, Gaithersburg) at RT.
2.7. A  ˇ measurements in brain tissue by ELISA
Using highly speciﬁc antibodies and a sensitive sandwich ELISA,
we quantiﬁed insoluble A40 and A42 in brain homogenates
extracted with TBS, 2% SDS and 70% formic acid according to
the method described [28]. The frozen brain tissue obtained from
rSeV-A-treated and rSeV-LacZ-treated Tg2576 mice (n = 4 each)
was  homogenized in 1 ml  of TBS/complete protease inhibitor and
20 g/ml pepstatin A (Roche, Indianapolis), then centrifuged at
100,000 × g for 1 h at 4 ◦C. The TBS supernatants were stored at
−80 ◦C and the pellets were homogenized in 1 ml of 2% SDS/TBS
with protease inhibitor (Roche), then centrifuged at 100,000 × g
for 1 h at 25 ◦C following 15 min  incubation at 37 ◦C. The pellet
was  washed once, then extracted further with 1 ml  of 70% formic
acid, and centrifuged at 100,000 × g for 1 h. The 70% formic acid
extracts were neutralized with 1 M Tris–HCl, pH 8.0 at dilution ofwith standard dilution buffer at 1:2000 for A40 or 1:400 for A42
and measured according to the manufacturer’s instructions. The
obtained values were corrected with the wet weight of each brain
hemisphere samples and expressed as pmol/g brain.
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.8. Western blot analysis for detection of A  ˇ oligomers in soluble
raction
For analysis of A oligomers in the SDS soluble fractions, 5 l
f the supernatant referring to the sample preparation in ELISA
as electrophoresed on 15/25% gradient SDS-PAGE gel (Daiichi,
apan) and transferred onto 0.2 m nitrocellulose membrane at
00 mA  for 1 h. Filters were blocked with 5% non-fat milk in a 20 mM
ris–HCl, pH 7.4 containing 150 mM NaCl and 0.05% Tween 20 (TBS-
). After washing the membranes in TBS-T, monoclonal anti-A
ntibody 6E10 (Senetek, Napa, CA) was used to probe the blots.
ound antibody was visualized using horseradish peroxidase-
onjugated anti-mouse IgG (at 1:10,000) and ECL + detection
Amersham Pharmacia Biotech, Arlington Heights, IL).
.9. Immunohistochemistry
Cryosections were ﬁxed for 15 min  with 70% formic acid for A
taining or 4% paraformaldehyde in 0.1 M phosphate buffer and
insed with PBS–Triton before incubation in 0.3% H2O2 in methanol
or 30 min. Sections were incubated at RT for 2 h with antibody
s indicated below. Sections were washed with PBS–Triton before
ncubation with secondary goat anti-mouse or anti-rabbit antibod-
es for 2 h. After PBS–Triton washes, sections were stained by the
vidin–biotin HRP/DAB method. For immunoﬂuorescent labeling,
he ﬂuorochromated immunoreagents were applied at a concentra-
ion of 20 g/ml PBS containing 1% BSA and 2% normal goat serum.
 plaque-containing sections were stained with polyclonal rab-
it anti-A antibody (Senetek, Napa, CA). The following primary
ntibodies were used at 1:50: CD3e, CD4, CD86, CD19 and CD11b
BD Biosciences Pharmingen, San Jose, CA), Cy3-tagged anti-mouse
FAP (Sigma, Saint Louis, MS;  1:400), and Iba-1 for microglia (kind
ift from Dr. U. Imai, NCNP, Tokyo).
Quantitative analysis of A burden was performed as described
reviously [21] in three different brain regions, the hippocampus,
he frontal cortex, and the parietal association cortex of rSeV-
acZ-treated and rSeV-A-treated Tg2576 mice (n = 4 each). The
 burden was deﬁned as the percentage of a brain region cov-
red by A-immunoreactive deposits. Images were projected from
n Olympus Vanox microscope onto a computer screen through
 3CCD Fujix digital camera and analyzed with an image analysis
ystem (Mac Scope, Mitani Corporation).
.10. Behavioral analysis
.10.1. Experimental design
Cognitive dysfunctions are directly correlated with A
ligomers in Tg2576 mice, which start at around 6 months old and
re stable until 14 months old [29]. Thus, we ﬁrst evaluated cogni-
ive functions in both non-tg (n = 18) and Tg2576 mice (n = 24) at
he age of 12 months. After the behavioral test, mice were divided
nto two groups to be treated with rSeV-LacZ or rSeV-A. There
s no difference between the two groups in behavioral scores at
he age of 12 months. To evaluate the effect of vaccine treatment,
ach group (rSeV-LacZ-treated non-tg mice, n = 9; rSeV-A-treated
on-tg mice, n = 9; rSeV-LacZ-treated Tg2576 mice, n = 10; rSeV-
-treated Tg2576 mice, n = 14) was subjected to behavioral tests
t the age of 15 months. All tests were done according to the meth-
ds described previously [30].
.10.2. Novel-object recognition test
24 h after 10 min-training session following 3 day-habituation,ach mouse was placed back into the same box in which one of
he familiar objects used during training was replaced with a novel
ne. The animals were then allowed to explore freely for 10 min  and
he time spent exploring each object was recorded. The exploratory (2011) 7474– 7482
preference (%), a ratio of the amount of time spent exploring any one
of the two objects (training session) or the novel object (retention
session) over the total time spent exploring both objects was used
to measure cognitive function.
2.10.3. Spontaneous alternation in a Y-maze test
Each mouse was  placed at the center of the apparatus and
allowed to move freely through the maze during an 8-min session,
and the series of arm entries was  recorded visually. Alternation
was  deﬁned as successive entry into the three arms on overlapping
triplet sets. The % alternation was  calculated as the ratio of actual
alternations to the possible alternations (deﬁned as the number of
arm entries minus two) multiplied by 100.
2.10.4. Morris water maze test
The Morris water maze test was  conducted in a circular pool
(1.2 m in diameter) with a hidden platform (7 cm in diameter) ﬁlled
with water at a temperature of 22 ± 1 ◦C. The mice were given two
trials (one block) for 10 consecutive days during which the platform
was  left in the same position. The time and distance taken to reach
to the escape platform (escape latency and distance moved) was
determined in each trial by using the Etho Vision system (Brain-
science Co. Ltd., Osaka, Japan). Three hours after the last training
trial, the platform was  removed, and mice were allowed for 60 s to
search the removed platform.
2.10.5. Cued and contextual fear conditioning tests
For measuring basal levels of freezing response (preconditioning
phase), mice were individually placed in a neutral cage for 1 min,
and then in the conditioning cage for 2 min. For conditioning, mice
were placed in the cage, and an 80 dB tone was delivered for 15 s.
During the last 5 s of the tone stimulus, a foot shock of 0.6 mA  was
delivered as an unconditioned stimulus through a shock generator
(Brainscience idea Co. Ltd.). This procedure was  repeated four times
with 15-s intervals. Cued and contextual tests were carried out 1
day after fear conditioning. For the cued test, the freezing response
was  measured in the neutral cage for 1 min  in the presence of a
continuous-tone stimulus identical to the conditioned stimulus. For
the contextual test, mice were placed in the conditioning cage, and
the freezing response was measured for 2 min  in the absence of the
conditioned stimulus.
2.10.6. Statistic analysis
All results were expressed as the mean ± S.E.M. for each group.
The difference among groups was  analyzed with a one-way, two-
way, or repeated ANOVA, followed by the Student–Newman–Keuls
multiple range-test. The Student’s t-test was  used to compare two
sets of data.
3. Results
3.1. Antibody response in the SeV-Aˇ-treated APP-tg mice
IgG antibodies to A were detected in the serum of nasally
treated Tg2576 mice with rSev-A at 4 weeks and less amount at 8
weeks after vaccination (Fig. 2a). However, intramuscularly treated
mice showed poor antibody response (not shown). The immune
sera from nasally vaccinated mice stained the senile plaque amyloid
in the tissue.
3.2. Reduction of A  ˇ burden after nasal vaccine with rSeV-Aˇ  in
Tg2576 miceNasal vaccination with rSeV-A resulted in marked reduction
of A burden in the frontal cortex, parietal association cortex and
hippocampus compared to the control (Fig. 2b and c). Thioﬂavin
H. Hara et al. / Vaccine 29 (2011) 7474– 7482 7477
Fig. 2. Effect of nasal vaccination with rSeV-A in 24-month-old Tg2576 mice. (a) Nasal vaccination with rSeV-A efﬁciently induced anti-A antibodies in Tg2576 mice.
Serum  anti-A IgG antibodies were measured by ELISA for Tg2576 mice (n = 4) treated with rSeV-A as well as for control untreated Tg2576 mice (n = 4). No. 1–4 corresponds
to  each individual mouse. Solid bars, 4 weeks after vaccination; open bars, 8 weeks after vaccination. (b–e) Sagital brain sections of Tg2576 mice treated with nasal (b and c)
or  intramuscular (d and e) administration of rSeV-LacZ (b and d) or rSev-A (c and e) were stained for A deposits with polyclonal anti-A antibodies. Parenchymal amyloid
plaques are apparently reduced when rSeV-A is given nasally. Scale bar: 100 m.  (f and g) A quantitative analysis shows that A deposits were signiﬁcantly reduced in
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pg2576 mice treated nasally with rSeV-A (f), while no signiﬁcant reduction was ob
lices  from each mouse.
-positive senile plaques were also signiﬁcantly reduced in vac-
inated mice. However, intramuscular injection of rSeV-A had
ittle effects on A clearance (Fig. 2d and e). Quantitative analyses
howed a marked reduction of A deposition in nasally vaccinated
ice compared to the control (Fig. 2f), but intramuscular injection
howed no difference in A clearance (Fig. 2g).
To investigate the expression of A43 in the olfactory bulb and
rain stem through trafﬁcking of rSeV via the olfactory or trigem-
nal nerves, we stained the brain tissue with anti-A43 antibody.
lthough Tg2576 mice expressed very little endogenous A43, we
ould not ﬁnd any A43 depositions after the nasal administration
f rSeV-A (data not shown).
.3. A  ˇ contents in brain homogenates and Western blot analysis
f Aˇ*56 oligomer
Soluble/insoluble A40 and A42 in brain homogenate fractions
xtracted with TBS or 2% SDS and 70% formic acid were quantiﬁed
sing the sandwich ELISA.
Nasal vaccination of rSeV-A signiﬁcantly reduced the contents
f soluble and insoluble A40 and A42 compared to the control
A40 in TBS, p = 0.04; 2% SDS, p = 0.027; formic acid, p = 0.001. A42
n TBS, p = 0.008; 2% SDS, p = 0.01; formic acid, p = 0.045.) (Fig. 3A),
ut again intramuscular injection of rSeV-A was ineffective (A40
n TBS, p = 0.3; 2% SDS, p = 0.45; formic acid, p = 0.41. A42 in TBS,
 = 0.15; 2% SDS, p = 0.27; formic acid, p = 0.48) (Fig. 3B). in mice treated intramuscularly (g). All data are the mean ± S.D. from four different
The trimeric, tetrameric, nonameric and dodecameric (A*56)
A oligomers in soluble fraction of Tg2576 mice were detected by
using Western blotting. Nasal vaccination with rSeV-A in Tg2576
mice resulted in a marked reduction in the contents of A*56 (dode-
camer) but not in soluble sAPP (Fig. 3C).
3.4. Absence of brain inﬂammation and synaptic restoration after
nasal vaccination with rSeV-Aˇ
HE staining of the brain sections of the vaccinated mice
showed no lymphocyte inﬁltrations in the leptomeninges or brain
parenchyma, and immunohistochemistry did not reveal any lym-
phocyte inﬁltrations, including CD3+, CD4+ and CD8+ T cells and
CD19+ B cells (data not shown).
In the hippocampus of the control APP-tg mice, there were many
Iba-1+ and CD11b− microglia cells surrounding the senile plaques
(Fig. 4a), while nasally vaccinated mice with rSeV-A showed the
uniform distribution of Iba-1+ CD11b+ microglia (Fig. 4b). GFAP
positive cells were less frequent in mice nasally vaccinated with
rSeV-A.Synaptophysin immunoreactivity was  shrunken and disrupted
in control mice with rSeV-LacZ. The nasally vaccinated mice with
rSeV-A showed the amelioration of abnormal change in synaptic
densities and distribution patterns (Fig. 4c and d).
7478 H. Hara et al. / Vaccine 29 (2011) 7474– 7482
Fig. 3. Changes of brain A levels after the nasal treatment with rSeV-A. Nasal rSeV-A vaccine efﬁciently reduced the A40 and 42 levels in both soluble and insoluble
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ice  (n = 4) (C).
.5. Effect of rSeV-Aˇ  on the body weight in Tg2576 mice
We examined the changes of body weight in Tg2576 mice
reated with SeV-A  nasally at the age of 12 months. The
ody weight measured at the age of 15 months was 28.2 ± 1.4 g
or rSeV-LacZ-vaccinated non-tg mice, 26.3 ± 1.1 g for rSeV-A-
accinated non-tg mice, 23.8 ± 0.9 g for rSeV-LacZ-vaccinated
g2576 mice, and 22.6 ± 0.7 g for rSeV-A-vaccinated Tg2576
ice. Results with the two-way ANOVA were signiﬁcantly dif-
erent in genotype (F(1,38) = 17.08, p < 0.01) but not vaccination
F(1,38) = 2.24, p = 0.14) nor interaction of genotype with vaccina-
ion (F(1,38) = 0.10, p = 0.74).
.6. Effect of nasal vaccination with rSeV-A  ˇ on the impaired
earning and memory.6.1. Object recognition in a novel-object recognition test
During the training session, there were no signiﬁcant differ-
nces in exploratory preference between the two objects and totalZ treated Tg2576 mice, n = 4; rSeV-A/mIL-10 treated Tg2576 mice, n = 4. Solid bars,
tly reduced in rSeV-A-treated mice nasally (n = 4) compared to rSeV-LacZ-treated
exploratory time among the groups (data not shown), suggesting
that all groups of mice have the same levels of motivation, curios-
ity, and interest in exploring novel objects. For the retention session
at age 12 months, the level of exploratory preference for the novel
object in Tg2576 mice was signiﬁcantly decreased compared to that
in non-tg mice (supplemental Fig. 1).
At age 15 months, the rSeV-LacZ-vaccinated Tg2576 mice also
showed a signiﬁcant reduction in the exploratory preference for
the novel object compared with rSeV-LacZ-vaccinated non-tg mice,
however rSeV-A vaccination improved the impairment of recog-
nition memory in Tg2576 mice signiﬁcantly (supplemental Fig. 1).
3.6.2. Spontaneous alternation in a Y-maze test
There was  no signiﬁcant difference in the number of arm entries
among the groups (data not shown), suggesting that all mice have
the same levels of motivation, curiosity, and motor function. At
age 12 months, Tg2576 mice showed signiﬁcantly reduced sponta-
neous alternation behavior in a Y-maze test compared with non-tg
mice (Fig. 5a). At age 15 months, the rSeV-LacZ-vaccinated Tg2576
H. Hara et al. / Vaccine 29 (2011) 7474– 7482 7479
F a-1+ m
(  rSev-
c  Scale
m
t
h
T
3
c
i
r
l
s
d
t
T
c
w
f
f
a
m
e
3
t
c
t
T
t
1
T
r
mig. 4. Immunohistochemical staining of microglia and synapses. There are many Ib
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ontrol  mice (c), whereas amelioration is obvious in mice treated with rSev-A (d).
ice also showed a signiﬁcant reduction in spontaneous alterna-
ion behavior compared with rSeV-LacZ-vaccinated non-tg mice,
owever rSeV-A vaccination improved alternation behavior in
g2576 mice signiﬁcantly (Fig. 5b).
.6.3. Associative learning in the cued and contextual fear
onditioning tests
In the preconditioning phase, the mice hardly showed any freez-
ng response. There were no differences in basal levels of freezing
esponse between the groups (data not shown). In the contextual
earning test, the rSeV-LacZ- and rSeV-A-vaccinated non-tg mice
howed a marked contextual freezing response 24 h after fear con-
itioning. There was no difference in freezing response between
he two groups of non-tg mice. However, the rSeV-LacZ-vaccinated
g2576 mice exhibited signiﬁcantly less freezing response in the
ontextual tests, indicating an impairment of associative learning,
hile the rSeV-A-vaccinated Tg2576 mice were indistinguishable
rom the rSeV-LacZ-vaccinated non-tg mice (Fig. 5c).
In the cued learning test, there was no difference in the cued
reezing response 24 h after fear conditioning among the groups. No
lterations of nociceptive response were found in any of the mutant
ice: there was no difference in the minimal current required to
licit ﬂinching or jumping among the mice (Fig. 5d).
.6.4. Reference memory in the Morris water maze test
At the age 12 months, Tg2576 mice took signiﬁcantly longer
ime and distance to reach the platform than non-tg mice, indi-
ating an impairment of reference memory (Fig. 6A and B). When
he transfer test was carried out following the tenth training trial,
g2576 mice showed a signiﬁcant decrease in the time spent in
he trained quadrant compared to non-tg mice (Fig. 6C). At age
5 months, rSeV-A vaccination improved all these parameters in
g2576 mice signiﬁcantly (Fig. 6D–F). The decreased ability of the
SeV-LacZ-vaccinated Tg2576 mice did not reﬂect a loss of swim-
ing ability and motivation because swimming speed and distanceicroglia surrounding senile plaques in the brain of rSeV-LacZ-treated Tg2576 mice
A (b). Synaptophysin staining shows disruption of synapses in rSeV-LacZ-treated
 bar: 100 m.
in the transfer test were similar to those in other mice (data not
shown).
4. Discussion
There are numerous approaches in active immunization ther-
apies for AD [31]. An interesting approach to avoid autoimmune
encephalitis is to avoid use of autoantigen A. Nasal administra-
tion of glatiramer acetate (GA) and adjuvant [32] or subcutaneous
administration of GA alone [33] is reported safe and effective in
Alzheimer model mice. GA is a synthetic random polymer com-
posed of alanine, lysine, tyrosine and glutamic acid, which is now
used for treatment of multiple sclerosis (MS). It has been speculated
that GA activates regulatory T cells against myelin antigen-reactive
auto-aggressive T cells, which in turn activates microglia, resulting
in increased phagocytosis of amyloid. However, such non-speciﬁc
clearance may  not last for long. Further, GA must be injected every-
day in MS.
Our nasal vaccine seems to be safe, easy, non-invasive and
long lasting. Long term expression of recombinant protein in the
mucosal epithelial cells and antigen presentation to the mucosal
immune system have many advantages such as less frequent
administrations and induction of continuous speciﬁc antibody
production. In addition, majority of administered DNA is sponta-
neously eliminated in accordance with epithelial cell renewal.
SeV belonging to the Genus Respirovirus, infects and multiplies
its genome copy in most mammalian cells, and expresses high
levels of the transgene. Its replication is independent of nuclear
functions and does not have a DNA phase during its life cycle, so it
does not need to be concerned about the transformation of cells by
integration of vector materials into the host chromosomes. These
properties are very promising devices for gene therapy of new
age (Cytoplasmic Gene Therapy) because of its genotoxicity-free
nature. Further, it is non-pathogenic for humans.
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Fig. 5. Effect of nasal vaccination with rSeV-A on Y-maze test, and cued and contextual fear conditioning tests. (a) Percent alternation during an 8-min session in the
Y-maze  tested in 12-month-old mice. Values indicate the mean ± S.E.M. *p < 0.05 vs non-transgenic mice (Student’s t-test). (b) Y-maze test done 3 months after vaccination.
Values indicate the mean ± S.E.M. Results with the two-way ANOVA were: genotype; F(1,38) = 7.17, p < 0.05, vaccination; F(1,38) = 2.40, p = 0.13, interaction of genotype with
vaccination; F(1,38) = 4.53, p < 0.05, **p < 0.01 vs rSeV-LacZ-vaccinated non-tg mice. #p < 0.05 vs rSeV-LacZ-vaccinated Tg2576 mice. N, non-tg mice; TG, Tg2576 mice; C,
rSeV-LacZ-treated mice; V, rSev-A-treated mice. (c and d) Effect of oral vaccination with rSeV-A/mIL-10 on associative learning in a conditioned-fear learning test. The
retention session was carried out 24 h after the training. Vaccine was given at 12 months and context-dependent (c) and tone-dependent (d) freezing time was measured at
15  months after the birth. Values indicate the mean ± S.E.M. Results with the two-way ANOVA were: context-dependent test: genotype; F(1,38) = 1.06, p = 0.31, vaccination;
F(1,38)  = 1.17, p = 0.29, interaction of genotype with vaccination; F(1,38) = 6.72, p < 0.05, cue-dependent test: genotype; F(1,38) = 1.25, p = 0.27, vaccination; F(1,38) = 0.78,
p  = 0.38, interaction of genotype with vaccination; F(1,38) = 1.44, p = 0.24. *p < 0.05 vs rSeV-LacZ-vaccinated non-transgenic mice. #p < 0.05 vs rSeV-LacZ-vaccinated Tg2576
m , non
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bice.  C, rSeV-LacZ vaccination; V, rSeV-A/mIL-10 vaccination; TG, Tg2576 mice; N
Since Sendai virus is a murine parainﬂuenza virus (PIV) with
ertain homologies to human PIV, it was tested as xenotropic vac-
ine in African Green monkeys and humans without any signiﬁcant
dverse reactions [34,35].  Recombinant SeV vector carrying human
IV was also tested in rats [36,37]. Further, recombinant SeV vac-
ine for human immunodeﬁciency virus (HIV) infection is going
o be tested in humans (http://www.dnavec.co.jp/en/index.html).
hus, safety of Sendai virus vector is gradually established.
We  inserted mouse IL-10 cDNA to construct rSeV-A with the
im of helping antibodies productions and suppressing Th1 type T
ell activations. Nasal administration of rSeV-A without IL-10 had
ess effect to remove A depositions (data not shown).Recently, soluble A oligomers, but not ﬁbrils nor monomers,
ave been considered responsible for cognitive dysfunction prior
o the formation of A plaques [22], and A*56, a 56-kDa solu-
le A dodecamer was found responsible in Tg2576 mice [29]. Our-transgenic mice.
nasal vaccine efﬁciently reduced not only senile plaque amyloid but
also the contents of A*56 oligomer without changing sAPP and
improved cognitive dysfunction in water maze, Y-maze and contex-
tual fear test which could evaluate hippocampus-related cognition.
Thus, our vaccine, if applicable, can be given at the stage of mild
cognitive impairment or earlier.
A is released from presynaptic sites and deposited in extra-
cellular plaques [38], and APP and synaptophysin are co-localized
at the growth cones of developing neurons in culture [39]. These
reports have indicated that A deposition plays an important role
in degeneration of presynaptic structures. In addition, it is reported
that A oligomers directly disrupt synaptic structures [40]. In our
study, synaptophysin staining showed amelioration of presynaptic
degeneration following our nasal vaccine at 24 months old, sug-
gesting prevention of synaptic degeneration or repair of synaptic
structures after removal of A deposits including A oligomers.
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Fig. 6. Effect of nasal vaccination with rSeV-A on reference memory in Morris water maze test. Morris water maze test was done at the age of 12 months (A–C) and was
repeated 3 months after vaccination (D–F). All values indicate the mean and S.E.M. (A) Escape latency (Esc. Lat.) measured during a 60-s session in the water maze test. Results
with  the repeated ANOVA were: trial: F(9,360) = 9.24, p < 0.01, animal group: F(1,40) = 5.98, p < 0.05, interaction of trial with animal group: F(9,369) = 0.86, p = 0.56, **p  < 0.01
vs  non-tg mice. (B) Distance moved (Dist. Mov.) measured during a 60-s session in the water maze test. Results with the repeated ANOVA were: trial: F(9,360) = 18.27,
p  < 0.01, animal group: F(1,40) = 24.97, p < 0.01, interaction of trial with animal group: F(9,360) = 1.92, p < 0.05, **p  < 0.01 vs non-transgenic mice. (C) Spatial memory during
the  transfer test after the training. Percent search time of a platform location during a 60-s session in the water maze test was measured. *p < 0.05 vs non-tg mice (Student’s
t-test).  (D) Same test as (A). Results with the repeated ANOVA were: trial: F(9,342) = 9.92, p < 0.01, animal group: F(3,38) = 3.56, p < 0.05, interaction of trial with animal group:
F(27,342) = 0.83, p = 0.71, **p < 0.01 vs rSeV-LacZ-vaccinated non-tg mice. ##p < 0.01 vs rSeV-LacZ-vaccinated Tg2576 mice. (E) Same test as (B). Results with the repeated
ANOVA were: trial: F(9,342) = 16.16, p < 0.01, animal group: F(3,38) = 9.45, p < 0.01, interaction of trial with animal group: F(27,342) = 1.00, p = 0.46, **p  < 0.01 vs rSeV-LacZ-
vaccinated non-tg mice. ##p < 0.01 vs rSeV-LacZ-vaccinated Tg2576 mice. (F) Same test as (C). Results with the two-way ANOVA were: genotype; F(1,38) = 6.56, p < 0.05,
vaccination; F(1,38) = 0.48, p = 0.49, interaction of genotype with vaccination; F(1,38) = 1.37, p = 0.25, *p < 0.05 vs rSeV-LacZ-vaccinated, non-transgenic mice.
7 ine 29
O
o
2
5
a
c
i
e
a
A
N
t
g
l
L
(
e
A
S
I
A
t
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[482 H. Hara et al. / Vacc
ur next plan is to see whether Tg2576 mice show improvement
f cognitive functions by eliminating senile plaque amyloid even at
4 months old.
. Conclusion
In conclusion, a new vaccine using Sendai virus vector with A
nd IL-10 cDNA was developed. A nasal administration of this vac-
ine reduced amyloid burden including A oligomers signiﬁcantly
n AD mice and improved cognitive functions without causing side
ffects such as brain inﬂammation. This vaccine can be used to treat
nd prevent Alzheimer disease.
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